| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $19.25 | $9,623.00 | -0.7% | |
| Dec 2, 2019 | TLRY Tilray Brands, Inc. | Auerbach Michael | Director | Sell | 40,312 | $19.07 | $768,663.09 | -32.2% | |
| Dec 2, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 4,310 | $10.49 | $45,214.49 | -17.3% | |
| Nov 27, 2019 | ZTS Zoetis Inc. | Knupp Catherine A. | Executive Vice President | Sell | 28,563 | $121.37 | $3,466,792.05 | -21.5% | |
| Nov 27, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 48,953 | $117.51 | $5,752,256.53 | - | |
| Nov 27, 2019 | BUDZ Weed, Inc. | Kwestel Elliot | Director Of Weed Israel Ltd. | Sell | 29,950 | $0.39 | $11,767.50 | -3.8% | |
| Nov 26, 2019 | ORGO Organogenesis Holdings Inc. | Avista Capital Managing Member Iv, LLC | Director, 10% Owner | Buy | 6,000,000 | $5.00 | $30,000,000.00 | +31.6% | |
| Nov 26, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 56,729 | $117.81 | $6,683,470.41 | - | |
| Nov 25, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 109,318 | $117.60 | $12,855,796.80 | - | |
| Nov 22, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 251,736 | $116.25 | $29,263,596.36 | -0.1% | |
| Nov 22, 2019 | ELAN Elanco Animal Health Inc | Bilbrey John P49 | Director | Buy | 3,766 | $26.58 | $100,100.28 | +47.8% | |
| Nov 21, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 108,264 | $115.14 | $12,465,506.13 | - | |
| Nov 21, 2019 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 11,425 | $119.67 | $1,367,229.75 | -49.9% | |
| Nov 21, 2019 | ZTS Zoetis Inc. | Fenton Andrew | Executive Vice President | Sell | 12,705 | $120.30 | $1,528,411.50 | -37.1% | |
| Nov 20, 2019 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Buy | 50,000 | $3.44 | $172,000.00 | +6.0% | |
| Nov 20, 2019 | AKBA Akebia Therapeutics, Inc. | Smith Cynthia | Director | Buy | 15,000 | $3.52 | $52,800.00 | +109.5% | |
| Nov 20, 2019 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Buy | 27,000 | $3.58 | $96,660.00 | +270.0% | |
| Nov 20, 2019 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 1,176 | $44.14 | $51,908.64 | -10.1% | |
| Nov 20, 2019 | AKBA Akebia Therapeutics, Inc. | Adams Adrian | Director | Buy | 50,000 | $3.41 | $170,500.00 | +365.0% | |
| Nov 20, 2019 | AKBA Akebia Therapeutics, Inc. | Gilman Steven C70 | Director | Buy | 5,800 | $3.43 | $19,894.00 | +24.2% | |
| Nov 19, 2019 | AMRN Amarin Corp Plc\uk | Thero John F | President And CEO | Sell | 274,454 | $22.65 | $6,217,371.13 | -10.5% | |
| Nov 19, 2019 | ZTS Zoetis Inc. | Alaix Juan Ramon | Chief Executive Officer | Sell | 50,000 | $119.13 | $5,956,500.00 | -34.2% | |
| Nov 19, 2019 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 4,463 | $118.99 | $531,052.37 | -13.4% | |
| Nov 19, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 205,000 | $115.06 | $23,586,775.90 | - | |
| Nov 18, 2019 | BCRX Biocryst Pharmaceuticals Inc | Ingram Robert Alexander | Director | Buy | 20,000 | $1.45 | $29,000.00 | +71.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.